Unilever plc vs Zoetis Inc — how do they compare? Unilever plc trades at $61.66 (market cap $131.63B), while Zoetis Inc trades at $73.24 (market cap $30.20B). The key difference: Unilever plc is far larger — about 4.4× Zoetis Inc's market cap, and Unilever plc pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Unilever plc for 112 Days and Zoetis Inc for 70 Days on average.
| UL | ZTS | |
|---|---|---|
Market Cap | $131.63B | $30.20B |
Volume | 2,978,741 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $74.59 | $147.53 |
52-Week Low | $55.05 | $69.09 |
Typical Hold Time | 112 Days | 70 Days |
Enterprise Value | $156.65B | $37.76B |
Dividend Yield | 3.43% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $1.83, narrowly missing the $1.84 estimate, continuing a trend of recent misses. Financially, UL maintains strong profitability with an 18.32% net income margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is divided with a Hold consensus, while news highlights strategic shifts including the planned food business merger with McCormick.
The outlook balances high profitability and emerging market exposure against execution risks from portfolio restructuring and recent earnings misses. The stock's valuation at a P/E of 21.32 appears reasonable relative to historical margins, but investor caution is warranted given the bearish technical trend and regulatory scrutiny of the McCormick deal. Upside potential hinges on successful integration and volume growth sustainability.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →